Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.

Pharmacogenomics - 1 Nov 2007

Etienne-Grimaldi Marie-Christine, Francoual Mireille, Formento Jean-Louis, Milano Gérard

Abstract excerpt

5-fluorouracil (5FU)-based treatments remain the main chemotherapy for colorectal cancer. Optimal cytotoxicity of fluoropyrimidines requires elevated CH(2)FH(4) tumoral concentrations, controlled by the methylenetetrahydrofolate reductase (MTHFR) enzyme, which irreversibly converts CH(2)FH(4) into 5-methyltetrahydrofolate. The MTHFR gene is subject to several polymorphisms, of which the 677C>T and 1298A>C SNPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Biotransformation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Colorectal Neoplasms

Share to Fluorouracil

Share to Genetic Variation

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Tetrahydrofolates

Source

Identifiers

PMID: 18034621
DOI: 10.2217/14622416.8.11.1561

Genes

MTHFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.PMID 18034621Read ↗

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patientsSemantic proximity Read ↗

5‐Fluorouracil‐based chemotherapy for colorectal cancer and MTHFR/MTRR genotypesSemantic proximity Read ↗

Role of the MTHFR polymorphisms in cancer risk modification and treatment.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.Semantic proximity Read ↗

Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5-fluorouracil and folinic acid.Semantic proximity Read ↗

Pharmacogenetic relevance of MTHFR polymorphisms.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase genotypes and haplotypes associated with susceptibility to colorectal cancer in an eastern Chinese Han population.Semantic proximity Read ↗

MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.Semantic proximity Read ↗

A study of the MTHFR gene polymorphism C677T in colorectal cancer.Semantic proximity Read ↗

A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.